Neurotech International Ltd Asset Resilience Ratio
Neurotech International Ltd asset resilience ratio. Neurotech International Ltd (NTI) has an Asset Resilience Ratio of 0.22% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See NTI defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Neurotech International Ltd (2016–2025)
Asset resilience ratio of Neurotech International Ltd from 2016 to 2025. This chart shows how Neurotech International Ltd's Asset Resilience Ratio has changed over time. Read debt load of Neurotech International Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Neurotech International Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Neurotech International Ltd assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$15.00K | 0.22% |
| Total Liquid Assets | AU$15.00K | 0.22% |
Asset Resilience Insights
- Limited Liquidity: Neurotech International Ltd maintains only 0.22% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Neurotech International Ltd Industry Peers by Asset Resilience Ratio
Compare Neurotech International Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Abivax SA
PA:ABVX |
Biotechnology | 2.58% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Sinocelltech Group Ltd
SHG:688520 |
Biotechnology | 5.27% |
|
Inner Mongolia Furui Med Sci
SHE:300049 |
Biotechnology | 1.75% |
|
Mineralys Therapeutics, Inc. Common Stock
NASDAQ:MLYS |
Biotechnology | 78.33% |
|
GH Research PLC
NASDAQ:GHRS |
Biotechnology | 4.73% |
Neurotech International Ltd Asset Resilience Ratio by Year (2016–2025)
Neurotech International Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Neurotech International Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 0.46% | AU$15.00K ≈ $10.61K |
AU$3.24 Million ≈ $2.29 Million |
-77.44pp |
| 2024-06-30 | 77.91% | AU$9.52 Million ≈ $6.73 Million |
AU$12.21 Million ≈ $8.64 Million |
+39.95pp |
| 2023-06-30 | 37.96% | AU$2.02 Million ≈ $1.43 Million |
AU$5.31 Million ≈ $3.76 Million |
+37.21pp |
| 2022-06-30 | 0.74% | AU$15.00K ≈ $10.61K |
AU$2.02 Million ≈ $1.43 Million |
-95.69pp |
| 2021-06-30 | 96.43% | AU$4.83 Million ≈ $3.42 Million |
AU$5.01 Million ≈ $3.54 Million |
+48.40pp |
| 2018-06-30 | 48.03% | AU$2.21 Million ≈ $1.57 Million |
AU$4.61 Million ≈ $3.26 Million |
+3.50pp |
| 2017-06-30 | 44.53% | AU$2.21 Million ≈ $1.56 Million |
AU$4.95 Million ≈ $3.50 Million |
+41.28pp |
| 2016-06-30 | 3.25% | AU$500.00K ≈ $353.78K |
AU$15.37 Million ≈ $10.88 Million |
-- |
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, focuses on development of solutions for paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy in Australia. The company develops NTI164 to treat autism spectrum disorder, paediatric autoimmune neuropsychiatric disorders associated with streptococcal infections, paediatric acute… Read more